| Version 2.5.2.0 |
|
|
Abstract
Grant Number: 1R21NS053658-01 Project Title: Modulators of CL-dependent Transport Processes (RMI)
PI Information: Name Title DELPIRE, ERIC J. eric.delpire@vanderbilt.edu ASSOCIATE PROFESSOR Abstract: DESCRIPTION (provided by applicant): Coupled movement of Na+, K+, and Cl-through cell membranes occurs primarily through Na-K 2CI and K-CI co-transporters, which belong to the Slc12 family of membrane transporters. Until the identification of the multiple genes that constitute this family, the physiology of cation-chloride co-transporters was dominated by the critical role that some of these co-transporters play in water and ion homeostasis in the kidney. In fact, the co-transporters are best known through their inhibitors: the loop and thiazide diuretics which are widely used in clinical medicine to volume deplete patients. The cloning of the human and mouse genomes identified 9-10 members of the Slc12 family of solute carriers. Among them, 7 are functionally well characterized: there are 1 Na-CI co-transporters, 2 Na-K-2CI co-transporters, and 4 K-CI co-transporters. These transporters participate in a wide variety of function which range from fluid secretion/absorption in multiple epithelia, modulation of synaptic transmission, cell volume control and regulation, cell proliferation. Mutations in cation-chloride co-transporters are responsible for diseases such as salt wasting disorders and peripheral nerve degeneration. They are also possibly involved in hypertension, age-related loss of hearing, neurological and psychiatric disorders. Whereas loop diuretics such as furosemide and bumetanide inhibit most cation-chloride co-transporters, these drugs are rather unspecific and not very potent. Thus, there is a critical need for the development of new compounds targeting cation-chloride co-transporter function. The development of novel fluorescent-based reagents, sensitive to anions and cations, now permits the development of better methods for High Throughput Screening (HTS). We propose to 1) Develop a fluorescence-based assay to monitor the activity of cation-chloride co-transporters. This will be achieved through heterologous expression of NKCC1 and KCC2 together with anion-sensitive fluorescent protein in HEK-293 cells. Based on studies showing that K+ channels can carry thallium, we will also examine the feasibility of use of a thallium-sensitive indicator dyes. 2) Provide a validation the assay for High Throughput Screening. This will be achieved through a detailed analysis of effects of a known inhibitor (e.g. bumetanide) on fluorescent signals generated by the movement of the surrogate anion or cation through the cell membrane and a through a test screening of a library consisting of 10,000 compounds. The development of a High Throughput fluorescent method to measure cation-chloride co-transporter function will allow us to transit to actual HT screens to identify novel compounds targeting the function of cation-chloride co-transporters.
Public Health Relevance:
This Public Health Relevance is not available.Thesaurus Terms:
chloride ion, drug discovery /isolation, drug screening /evaluation, fluorescent dye /probe, high throughput technology, inhibitor /antagonist, membrane transport protein, technology /technique development
combinatorial chemistry, ion transport, thallium
biotechnology, cell line
Institution: VANDERBILT UNIVERSITY Medical Center NASHVILLE, TN 372036869 Fiscal Year: 2005 Department: ANESTHESIOLOGY Project Start: 30-SEP-2005 Project End: 31-AUG-2006 ICD: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE IRG: ZNS1